Compare Abeona Therapeutics Inc (ABEO) vs KLA Corp. (KLAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs KLA Corp. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while KLA Corp. trades at $219.6 (market cap $282.77B). The key difference: KLA Corp. is far larger — about 757.4× Abeona Therapeutics Inc's market cap, and KLA Corp. pays a 0.43% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | KLAC | |
|---|---|---|
Market Cap | $373.32M | $282.77B |
Sector | Health | Technology |
52-Week High | $7.23 | $301.71 |
52-Week Low | $4.17 | $84.39 |
Enterprise Value | $228.22M | $283.96B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
KLA Corporation (KLAC) trades at $216.47, down 8.1% over 24 hours, amid a broader semiconductor selloff. The stock maintains strong fundamentals with a 35.66% net income margin and consistent earnings beats, including Q1 2026 EPS of $0.94 versus $0.917 expected. A 1:10 stock split is scheduled for June 12, 2026, and the company pays a $2.30 dividend. Technical indicators show a bearish short-term trend with support near $209.
KLAC's outlook is supported by robust profitability and AI-driven demand, but high valuation ratios (P/E 66.07) pose risks. Analyst consensus is bullish with a $228.42 price target, though sector volatility and competitive pressures require monitoring. The stock offers growth potential tempered by market sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
